Nearly a Century of Insulin at Sanofi: Looking Back Over the Decades of Production and Development.
Clicks: 303
ID: 101274
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
303 views
48 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #3 of 5 articles by views in pediatric endocrinology reviews : per
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Almost a century ago, the first insulin was produced by Banting, Best, MacLeod and Collip in Toronto, thereby enabling life-saving treatment for people with diabetes. Since then, there have been many advancements in insulin production and development of new insulin analogues. In this article, we reflect on the rich heritage of Sanofi and its predecessor, Hoechst, in insulin production and development, from being one of the first companies to produce insulin in Europe in 1923, to modern-day insulin analogues and integrated care solutions at present-day Sanofi.
| Reference Key |
bosnyak2020nearlypediatric
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bosnyak, Zsolt;Korn, Marcus;Bielohuby, Maximilian;Wohlfart, Paulus;Tennagels, Norbert; |
| Journal | pediatric endocrinology reviews : per |
| Year | 2020 |
| DOI |
10.17458/per.vol17.2020.bkb.sanoficenturyinsulin
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.